Logo image of KTTA

PASITHEA THERAPEUTICS CORP (KTTA) Stock Fundamental Analysis

USA - NASDAQ:KTTA - US70261F2020 - Common Stock

0.7029 USD
-0.01 (-1%)
Last: 11/12/2025, 8:00:02 PM
Fundamental Rating

2

Taking everything into account, KTTA scores 2 out of 10 in our fundamental rating. KTTA was compared to 531 industry peers in the Biotechnology industry. KTTA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. KTTA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year KTTA has reported negative net income.
KTTA had a negative operating cash flow in the past year.
In the past 5 years KTTA always reported negative net income.
KTTA had a negative operating cash flow in each of the past 5 years.
KTTA Yearly Net Income VS EBIT VS OCF VS FCFKTTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

KTTA has a worse Return On Assets (-79.12%) than 67.04% of its industry peers.
KTTA has a Return On Equity (-88.66%) which is in line with its industry peers.
Industry RankSector Rank
ROA -79.12%
ROE -88.66%
ROIC N/A
ROA(3y)-32.01%
ROA(5y)N/A
ROE(3y)-35.08%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KTTA Yearly ROA, ROE, ROICKTTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

KTTA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KTTA Yearly Profit, Operating, Gross MarginsKTTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 -5K -10K -15K -20K -25K

More info and screens

6

2. Health

2.1 Basic Checks

KTTA has more shares outstanding than it did 1 year ago.
There is no outstanding debt for KTTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KTTA Yearly Shares OutstandingKTTA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
KTTA Yearly Total Debt VS Total AssetsKTTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -5.13, we must say that KTTA is in the distress zone and has some risk of bankruptcy.
KTTA has a worse Altman-Z score (-5.13) than 60.64% of its industry peers.
There is no outstanding debt for KTTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.13
ROIC/WACCN/A
WACCN/A
KTTA Yearly LT Debt VS Equity VS FCFKTTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

A Current Ratio of 4.97 indicates that KTTA has no problem at all paying its short term obligations.
The Current ratio of KTTA (4.97) is comparable to the rest of the industry.
A Quick Ratio of 4.97 indicates that KTTA has no problem at all paying its short term obligations.
KTTA's Quick ratio of 4.97 is in line compared to the rest of the industry. KTTA outperforms 56.50% of its industry peers.
Industry RankSector Rank
Current Ratio 4.97
Quick Ratio 4.97
KTTA Yearly Current Assets VS Current LiabilitesKTTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

0

3. Growth

3.1 Past

KTTA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 48.74%, which is quite impressive.
EPS 1Y (TTM)48.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KTTA Yearly Revenue VS EstimatesKTTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 100K 200K 300K 400K 500K
KTTA Yearly EPS VS EstimatesKTTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KTTA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KTTA Price Earnings VS Forward Price EarningsKTTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KTTA Per share dataKTTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

KTTA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PASITHEA THERAPEUTICS CORP

NASDAQ:KTTA (11/12/2025, 8:00:02 PM)

0.7029

-0.01 (-1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-11 2025-11-11
Earnings (Next)03-23 2026-03-23
Inst Owners9.26%
Inst Owner Change39.24%
Ins Owners1.51%
Ins Owner Change-0.02%
Market Cap5.23M
Revenue(TTM)N/A
Net Income(TTM)-13.46M
Analysts82.86
Price TargetN/A
Short Float %0.31%
Short Ratio0.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.34
P/tB 0.76
EV/EBITDA N/A
EPS(TTM)-7.68
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.68
FCFYN/A
OCF(TTM)-1.68
OCFYN/A
SpS0
BVpS2.04
TBVpS0.93
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -79.12%
ROE -88.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.01%
ROA(5y)N/A
ROE(3y)-35.08%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.97
Quick Ratio 4.97
Altman-Z -5.13
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1213.67%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.23%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y18.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-69.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-73.51%
OCF growth 3YN/A
OCF growth 5YN/A

PASITHEA THERAPEUTICS CORP / KTTA FAQ

What is the fundamental rating for KTTA stock?

ChartMill assigns a fundamental rating of 2 / 10 to KTTA.


What is the valuation status for KTTA stock?

ChartMill assigns a valuation rating of 0 / 10 to PASITHEA THERAPEUTICS CORP (KTTA). This can be considered as Overvalued.


What is the profitability of KTTA stock?

PASITHEA THERAPEUTICS CORP (KTTA) has a profitability rating of 0 / 10.


How financially healthy is PASITHEA THERAPEUTICS CORP?

The financial health rating of PASITHEA THERAPEUTICS CORP (KTTA) is 6 / 10.